MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on November 4, 2004; DOI: 10.1124/mol.104.006171


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.104.006171v1
67/2/394    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nowell, S.
Right arrow Articles by Kadlubar, F. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nowell, S.
Right arrow Articles by Kadlubar, F. F.


Received for publication August 16, 2004.
Revised November 2, 2004.
Accepted for publication November 2, 2004.

Examination of Human Tissue Cytosols for Expression of Sulfotransferase Isoform 1A2 (SULT1A2) Using a SULT1A2-specific Antibody

Susan Nowell 1*, Bridgett Green 2, Yong Ming Tang 3, Rick Wiese 4, Fred F. Kadlubar 5

1 Roswell Park Cancer Institute 2 National Center for Toxicological Research 3 Cedars-Sinai Medical Center 4 Pierce Biotechnology 5 National Center for Toxicology Research

* Address correspondence to: E-mail: susan.nowell{at}roswellpark.org

Abstract

SULT1A2 is a member of the cytosolic sulfotransferase family of phase II detoxification enzymes. Studies with recombinant enzymes have shown that SULT1A2 can catalyze the bioactivation of several procarcinogens, indicating a potential role in chemical carcinogenesis. However, previous studies have suggested that the SULT1A2 transcript has a splicing defect that might prevent it from becoming translated into protein; therefore, we sought to determine the expression of SULT1A2 in tissues. An antibody directed against a region of human SULT1A2 that differs from other known sulfotransferase isoforms was developed and used to screen a large number of cytosolic fractions from various tissues. Although the SULT1A2 antibody recognized recombinant SULT1A2 and did not cross-react with other SULT isoforms, the expression of SULT1A2 was not detected in any tissue examined. These studies suggest that if SULT1A2 is expressed as protein, the levels are very low and that SULT1A2 likely does not play a physiological role in chemical carcinogenesis.


Key words: Enzymology, Sulfotransferases, Genetics





Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics